COMP <GO>
VRTX vs JNJ // PIOTROSKI F-SCORE QUALITY
Vertex Pharmaceuticals Incorporated (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: VRTX 7
— JNJ 6
■ METRIC PARITY
LAST: $558.88 (+3.50%) • MKT CAP: $136.87B
piotroski-score
8/9
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
piotroski-score
8/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VRTX VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VRTX | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 86.20% | 67.90% | +18.30 | VRTX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 20.00% | 25.50% | -5.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 29.6x | 18.5x | +11.10 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 2.33% | 2.97% | -0.64 | JNJ | /fcf-yield <GO> |
| Operating Margin | 34.80% | 34.70% | +0.10 | VRTX | /operating-margins <GO> |
| Net Profit Margin | 32.90% | 28.50% | +4.40 | VRTX | /net-margins <GO> |
| Revenue Growth (YoY) | 8.90% | 6.00% | +2.90 | VRTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 13.86 | 5.59 | +8.27 | VRTX | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 7.20% | -0.20 | VRTX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 67.7 | 60.4 | +7.30 | VRTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.02 | 1.08 | -0.06 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.2x | 23.0x | +9.20 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $136.87B | $662.49B | -$525.62B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VRTX REV | JNJ REV | VRTX GROSS % | JNJ GROSS % | VRTX FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $12.00B | $94.19B | 86.2% | 67.9% | $3.19B | $19.70B |
| FY 2024 | $11.02B | $88.82B | 86.1% | 69.1% | -$790.3M | $19.84B |
| FY 2023 | $9.87B | $85.16B | 44.0% | 44.0% | $3.09B | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VRTX // BETA 1.02
JNJ // BETA 1.08